Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Opko Health Inc (OPK)

Opko Health Inc (OPK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 985,090
  • Shares Outstanding, K 665,601
  • Annual Sales, $ 990,270 K
  • Annual Income, $ -153,040 K
  • 60-Month Beta 2.17
  • Price/Sales 1.00
  • Price/Cash Flow N/A
  • Price/Book 0.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.08
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.33 +15.04%
on 10/25/19
2.43 -36.95%
on 10/21/19
-0.57 (-26.97%)
since 10/18/19
3-Month
1.33 +15.04%
on 10/25/19
2.43 -36.95%
on 10/21/19
-0.49 (-24.26%)
since 08/19/19
52-Week
1.33 +15.04%
on 10/25/19
3.93 -61.12%
on 01/11/19
-1.92 (-55.65%)
since 11/19/18

Most Recent Stories

More News
Novitas Issues Final Local Coverage Determination for the 4Kscore(R) Test

OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued its final Local Coverage Determination (LCD) for Medicare payments for the 4Kscore(R) test with defined coverage criteria,...

OPK : 1.53 (+3.38%)
OPKO Health (OPK) Q3 Earnings Miss Estimates, Revenues Beat

OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.

TMO : 306.42 (+1.80%)
OPK : 1.53 (+3.38%)
RMD : 149.39 (+1.09%)
EW : 243.56 (+0.49%)
OPKO Health (OPK) Reports Q3 Loss, Tops Revenue Estimates

OPKO Health (OPK) delivered earnings and revenue surprises of -22.22% and 1.92%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

OPK : 1.53 (+3.38%)
OPKO Health: 3Q Earnings Snapshot

MIAMI (AP) _ Opko Health Inc. (OPK) on Tuesday reported a loss of $62 million in its third quarter.

OPK : 1.53 (+3.38%)
OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results

OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2019.

OPK : 1.53 (+3.38%)
BioReference Laboratories and GeneDx to Present at NSGC 2019, Demonstrating Commitment to Genetic Counselors and the Research of Rare Genetic Disorders

BioReference Laboratories, Inc., an OPKO Health Company, along with its genetics and genomics laboratory, GeneDx, and women's health division, GenPath, today announced the presentation of new research...

OPK : 1.53 (+3.38%)
Earnings Preview: OPKO Health (OPK) Q3 Earnings Expected to Decline

OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OPK : 1.53 (+3.38%)
OPKO Health to Report Third Quarter 2019 Financial Results on November 5, 2019

OPKO Health, Inc. (NASDAQ: OPK) plans to report its operating and financial results for the three months ended September 30, 2019, as well as provide guidance on expected revenues and operating expenses...

OPK : 1.53 (+3.38%)
OPKO Health Enters Oversold Territory

OPKO Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

OPK : 1.53 (+3.38%)
OPKO Health, Inc. Announces Pricing of its Offering of Common Stock

OPKO Health, Inc. ("OPKO Health" or the "Company") (NASDAQ:OPK) today announced the pricing of an underwritten public offering of 50 million shares of its common stock (the "Shares") at a price of $1.50...

OPK : 1.53 (+3.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade OPK with:

Business Summary

OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.

See More

Key Turning Points

2nd Resistance Point 1.59
1st Resistance Point 1.56
Last Price 1.53
1st Support Level 1.47
2nd Support Level 1.42

See More

52-Week High 3.93
Fibonacci 61.8% 2.94
Fibonacci 50% 2.63
Fibonacci 38.2% 2.33
Last Price 1.53
52-Week Low 1.33

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar